



SPECIALTY GUIDELINE MANAGEMENT

FARYDAK (panobinostat)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered covered benefits provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy

A. FDA-Approved Indication

Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. This indication is approved under accelerated approval based on progression free survival. Continued approval of this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

B. Compendial Use

In combination with carfilzomib for the treatment of multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent

All other indications are considered experimental/investigational and are not covered benefits.

II. CRITERIA FOR INITIAL APPROVAL

Authorization of 12 months may be granted for the treatment of multiple myeloma when the member has received at least two prior regimens, including bortezomib and an immunomodulatory agent (eg, lenalidomide, thalidomide, pomalidomide).

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCES

- 1. Farydak [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February 2015.
- 2. The NCCN Drugs & Biologics Compendium[®] © 2016 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed October 20, 2016.
- 3. The NCCN Clinical Practice Guidelines in Oncology[®] Multiple Myeloma (Version 1.2017) © 2016 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed October 20, 2016.

Farydak SGM P2016x

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. ® Registered trademark of CareFirst of Maryland, Inc.